MADRONISH THERAPEUTICS

Madronish Therapeutics, LLC (MTL) is a biotechnology company focused on immuno-oncology strategies to either enhance immune response against cancer or suppress immune response underlying autoimmune inflammatory diseases. MTL is dedicated to the creation of novel, patented biologic therapeutics for their use in the treatment of medically unmet cancer and autoimmune/inflammatory diseases indications. Biologic therapeutics represent the single most clinically and commercially attractive compone... nt in the pharmaceutical industry. Collectively, current marketed biologic therapeutics represent >$40 billion in sales for their respective sponsors. MTL technology platform is based on the use of modular single chain antibody format that allows creation of bi-, tri- or multispecific biologic therapeutics. MTL therapeutic proteins are intended to and will be clearly differentiated from the current standards of care used in the therapy of cancer and autoimmune diseases. MTL will also focus on the generation of antibody-directed chemotherapy strategy of cancer using antibody drug conjugates. MTL founder has broad experience and track record of success in both these areas of therapeutic R&D. Bi- or tri-specific functionality of MTL therapeutic assets will offer therapeutic advantage of two or three premium priced individual therapeutics, combinations of which may be clinically beneficial but pharmacoeconomically unaffordable to both patients and payers. MTL therapeutics will deliver clinical benefit of two or three such therapeutics for the price of one and hence with affordable price points. Research activities of Madronish will be conducted in a virtual manner by collaborating with contract research organizations capable of undertaking integrated discovery and early development of biologic therapeutics. A 3-year blueprint of R&D activities has been created awaiting implementation. MTL is seeking seed funding for expeditious implementation of its research programs.More